Immunotherapy in head and neck cancer: Current practice and future possibilities

Journal of Laryngology and Otology

Volumn 123, Issue 1, 2009, Pages 19-28

  Agada, F O ^a   Alhamarneh, O ^a   Stafford, N D ^a   Greenman, J ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Head and Neck Neoplasms; Immunotherapy; Squamous Carcinoma

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DNA VACCINE; ERLOTINIB; GEFITINIB; INDOMETACIN; INTERLEUKIN 10; INTERLEUKIN 4; LEUKOCYTE ANTIGEN; MULTIVITAMIN; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 12; RITUXIMAB; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR CELL VACCINE; ZINC; CANCER VACCINE; CYTOKINE; MONOCLONAL ANTIBODY;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DENDRITIC CELL; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LOW DRUG DOSE; LYMPHOCYTE; REVIEW; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TREATMENT INDICATION; TREATMENT RESPONSE; HEAD AND NECK TUMOR; IMMUNOLOGY; METHODOLOGY; MULTIMODALITY CANCER THERAPY;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CYTOKINES; DENDRITIC CELLS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES;

EID: 64249084710     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215108003356     Document Type: Review

References (75)

1. Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer 2005;5:127-35
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64
3. Sykiotis GP, Papavassiliou AG. Apoptosis: the suicide solution in cancer treatment and chemoprevention. Expert Opin Investig Drugs 2006;15:575-7
4. Turk MJ, Wolchok JD, Guevara-Patino JA, Goldberg SM, Houghton AN. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev 2002;188:122-35
5. Miller SJ, Lavker RM, Sun TT. Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta 2005;1756:25 - 52
6. Topping KP, Fletcher L, Agada FO, Alhamarneh O, Stafford ND, Greenman J. Head and neck tumour immunology: basic concepts and new clinical implications. J Laryngol Otol (in press)
7. Jebreel A, Mistry D, Loke D, Dunn G, Hough V, Oliver K et al. Investigation of IL-10, IL-12 and IL-18 levels in patients with head and neck cancer. J Laryngol Otol 2007;121:246 - 52
8. O'Riordan JM, Abdel-Latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 2005; 100:1257-64
9. Riedel F, Zaiss I, Herzog D, Gotte K, Naim R, Hormann K. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res 2005;25:2761-5
10. van Sandick JW, Boermeester MA, Gisbertz SS, ten Berge IJ, Out TA, van der Pouw Kraan TC et al. Lymphocyte subsets and T(h)1/T(h)2 immune responses in patients with adenocarcinoma of the oesophagus or oesophago- gastric junction: relation to pTNM stage and clinical outcome. Cancer Immunol Immunother 2003;52:617-24
11. Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC, Capo DE et al. IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 2001;7:1812-20
12. Agarwal A, Rani M, Saha GK, Valarmathi TM, Bahadur S, Mohanti BK et al. Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Invest 2003;32:17-30
13. Sparano A, Lathers DM, Achille N, Petruzzelli GJ, Young MR. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2004;131:573- 6
14. Ogura M, Morishima Y, Kagami Y, Watanabe T, Itoh K, Igarashi T et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci 2006;97:305-12
15. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002;62:209- 43
16. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003;25:67-73
17. Coico R, Sunshine G, Benjamini E. Immunology: A short course, Chapter 19 Tumour Immunology pp273-85. 5th Ed. (2003), New Jersey, USA John Wiley & Sons Inc. 18 Li G, Ali SA, McArdle SE, Mian S, Ahmad M, Miles A et al. Immunity to tumour antigens. Curr Pharm Des 2005;11:3501-9
18. Kienstra MA, Neel HB, Strome SE, Roche P. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 2003;25:457-63
19. Lee KD, Chang HK, Jo YK, Kim BS, Lee BH, Lee YW et al. Expression of the MAGE 3 gene product in squamous cell carcinomas of the head and neck. Anticancer Res 1999: 19:5037 -42
20. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245 - 52
21. Barratt-Boyes SM, Watkins SC, Finn OJ. In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. J Immunol 1997;158:4543-7
22. Todryk S. A sense of tumour for the immune system. Immunology 2002;107:1-4
23. Mende I, Engleman EG. Breaking tolerance to tumors with dendritic cell-based immunotherapy. Ann N Y Acad Sci 2005;1058:96-104
24. Andre F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 2004;172:2126-36
25. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755-66
26. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166:678- 89
27. Tas MP, Simons PJ, Balm FJ, Drexhage HA. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol Immunother 1993;36:108-14
28. Kerrebijn JD, Simons PJ, Tas M, Balm AJ, Drexhage HA. In vivo effects of thymostimulin treatment on monocyte polarization, dendritic cell clustering and serum p15E-like trans-membrane factors in operable head and neck squamous cell carcinoma patients. Eur Arch Otorhi- nolaryngol 1995;252:409-16
29. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998;28:359-69
30. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772 -80
31. Peguet-Navarro J, Moulon C, Caux C, Dalbiez-Gauthier C, Banchereau J, Schmitt D. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. Eur J Immunol 1994;24:884-91
32. Kacani L, Wurm M, Schennach H, Braun I, Andrle J, Sprinzl GM. Immunosuppressive effects of soluble factors secreted by head and neck squamous cell carcinoma on dendritic cells and T lymphocytes. Oral Oncol 2003;39:672-9
33. Strauss L, Volland D, Kunkel M, Reichert TE. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angio- genesis and immune tolerance. Med Sci Monit 2005;11:BR280-92
34. Goldman SA, Baker E, Weyant RJ, Clark MR, Myers JN, Lotze MT et al. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otol Head Neck Surg 1998;124:641-6
35. Lathers DM, Achille N, Kolesiak K, Hulett K, Sparano A, Petruzzelli GJ et al. Increased levels of immune inhibitory CD34+ progenitor cells in the peripheral blood of patients with node positive head and neck squamous cell carcinomas and the ability of these CD34+ cells to differentiate into immune stimulatory dendritic cells. Otolaryngol Head Neck Surg 2001;125:205-12
36. Dong J, Bohinski RJ, Li YQ, Van Waes C, Hendler F, Gleich L. Antitumor effect of secreted Flt3-ligand can act at distant tumour sites in a murine model of head and neck cancer. Cancer Gene Ther 2003;10:96-104
37. Nix P, Stafford N, Cawkwell L, Greenman J. Assessment of dendritic cell number and radiosensitivity in laryngeal tumours. Clin Otolaryngol 2005;30:164-8
38. Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005;24:95-105
39. To WC, Wood BG, Krauss JC, Strome M, Esclamado RM, Lavertu P et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg 2000;126:1225-31
40. Chang AE, Li Q, Jiang G, Teknos TN, Chepeha DB, Bradford CR. Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer. Head Neck 2003;25:198-209
41. Karcher J, Dyckhoff G, Beckhove P, Reisser C, Brysch M, Ziouta Y et al. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus- modified tumor cells. Cancer Res 2004;64:8057-61
42. Herold-Mende C, Karcher J, Dyckhoff G, Schirrmacher V. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine. Adv Otorhinolaryngol 2005;62:173-83
43. Gleich LL, Collins CM, Gartside PS, Gluckman JL, Barrett WL, Wilson KM et al. Therapeutic decision making in stages III and IV head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2003;129:26-35
44. Weise JB, Maune S, Gorogh T, Kabelitz D, Arnold N, Pfisterer J et al. A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC. Auris Nasus Larynx 2004;31:149-53
45. Kacani L, Wurm M, Schwentner I, Andrle J, Schennach H, Sprinzl GM. Maturation of dendritic cells in the presence of living, apoptotic and necrotic tumour cells derived from squamous cell carcinoma of head and neck. Oral Oncol 2005;41:17-24
46. Cheah PL, Looi LM. p53: an overview of over two decades of study. Malays J Pathol 2001;23:9-16
47. Brown L, Benchimol S. The involvement of MAPK signaling pathways in determining the cellular response to p53 activation - cell cycle arrest or apoptosis. J Biol Chem 2006;281:3832-40
48. Nikitina EY, Clark JI, Van Beynen J, Chada S, Virmani AK, Carbone DP et al. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients Clin Cancer Res 2001;7:127-35
49. Hoffmann TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann U, Myers EN et al. Frequencies of tetramer+ T cells specific for the wild-type sequence p53 (264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res 2002;62:3521-9
50. Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild- type p53. Br J Cancer 2001;84:1052-7
51. Chikamatsu K, Nakano K, Storkus WJ, Appella E, Lotze MT, Whiteside TL et al. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 1999;5:1281-8
52. McArdle SE, Rees RC, Mulcahy KA, Saba J, McIntyre CA, Murray AK. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant. Cancer Immunol Immunother 2000;49:417-25
53. Hoffmann TK, Bier H, Donnenberg AD, Whiteside TL, De Leo AB. p53 as an immunotherapeutic target in head and neck cancer. Adv Otorhinolaryngol 2005;62:151-60
54. Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M et al. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Clin Cancer Res 2000;6:979-86
55. Asai T, Storkus WJ, Mueller-Berghaus J, Knapp W, DeLeo AB, Chikamatsu K et al. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including pep- tides derived from the p53 and MDM-2 proteins. Cancer Immun 2002;2:3
56. Bellier B, Dalba C, Clerc B, Desjardins D, Drury R, Cosset FL et al. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 2006;24:2643- 55
57. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003;21:4036-42
58. Prud'homme GJ. DNA vaccination against tumors. J Gene Med 2005;7:3-17
59. Miller AM, Ozenci V, Kiessling R, Pisa P. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother 2005;28:389-95
60. Vaccine Therapy With Immune Adjuvant in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma. http://www.clinicaltrials.gov/ct/ show/NCT 00085137 [Date last viewed, 06/03/2008]
61. Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation. http://www.clinicaltrial.gov/ct/ show/NCT00250276 [Date last viewed, 06/03/2008]
62. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:634-6
63. What is new in Head and Neck Cancer? http://www. cancerhelp.org.uk/trials [Date last viewed, 06/03/2008]
64. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315:971-9
65. Arteaga CL. Inhibiting tyrosine kinases: successes and limitations. Cancer Biol Ther 2003;2:S79-83
66. Arteaga CL, Baselga J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 2004;5:525-31
67. O'Malley BW Jr, Li D, McQuone SJ, Ralston R. Combination nonviral interleukin-2 gene immunotheraphy for head and neck cancer: from bench top to bedside. Laryngoscope 2005;115:391-404
68. van Herpen CM, Looman M, Zonneveld M, Scharenborg N, de Wilde PC, van de Locht L et al. Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes. Clin Cancer Res 2004;10:2626-35
69. Timar J, Ladanyi A, Forster-Horvath C, Lukits J, Dome B, Remenar E et al. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/ CD8 ratio and tumour microenvironment: a multicenter phase II clinical trial. J Clin Oncol 2005;23:3421 -32
70. Li D, Shugert E, Guo M, Bishop JS, O'Malley BW Jr. Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001;127:1319-24
71. MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck. http://www.clinicaltrials. gov/ct/show/NCT00257738 [Date last viewed, 06/03/2008]
72. A Phase 2 Clinical Trial of the Effectiveness of IRX-2 in Treating Patients With Operable Head and Neck Cancer. http://www.clinicaltrials.gov/ct/ show/NCT00210470 [Date last viewed, 06/03/2008]
73. Borjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2003;9:3961S-72S
74. Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ et al. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squa- mous cell carcinoma of the head and neck. J Nucl Med 2000;41:1999-2010
75. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85